1049695-95-5 Usage
General Description
4-Methoxy-alpha-methyl-N-(phenylmethyl)benzeneethanamine hydrochloride is a chemical compound that belongs to the class of drugs known as sympathomimetic amines. It is commonly used as a central nervous system stimulant and is also sometimes prescribed to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. 4-Methoxy-alpha-methyl-N-(phenylmethyl)benzeneethanamine hydrochloride works by increasing the levels of certain neurotransmitters in the brain, specifically dopamine and norepinephrine, leading to improved focus, attention, and alertness. However, it can also have potential side effects such as increased heart rate, elevated blood pressure, and insomnia. Due to its psychoactive properties, it is a controlled substance and its use should be closely monitored and regulated by a healthcare professional.
Check Digit Verification of cas no
The CAS Registry Mumber 1049695-95-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,9,6,9 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1049695-95:
(9*1)+(8*0)+(7*4)+(6*9)+(5*6)+(4*9)+(3*5)+(2*9)+(1*5)=195
195 % 10 = 5
So 1049695-95-5 is a valid CAS Registry Number.
1049695-95-5Relevant articles and documents
PROCESS FOR THE SYNTHESIS OF ARFORMOTEROL
-
Page/Page column 31-32, (2009/12/28)
The present invention provides a process for preparing a compound of formula (Vl) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an α-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (Vl), wherein the reduction is carried out in the presence of either (1 ) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein: R1 and R2 are independently optionally substituted arylalkyl, and Hal is selected from chloro or bromo.
